E-MTAB-1118 - Expression profiling of transgenic TH-MYCN mice with palpable tumors treated with MLN8054 or vehicle
Released on 1 July 2013, last updated on 3 May 2014
Transgenic TH-MYCN mice with palpable tumors (40-80 days old) treated with 40mg/kg MLN8054 or vehicle. MLN8054 was administered via oral gavage. Animals were sacrificed when pathologic signs of tumor burden (predominantly poor mobility) were apparent. Animals were treated in accordance with national animal welfare guidelines. Mice were allowed access to food and water ad libitum.
transcription profiling by array, cell type comparison
Small molecule inhibitors of Aurora-A induce proteasomal degradation of N-Myc in childhood neuroblastoma. Markus Brockmann, Evon Poon, Anne Carstensen, Hedwig Deubzer, Lukas Rycak, Teeara Berry, Yann Jamin, Khin Thway, Simon Robinson, Hermann Schindelin, Olaf Witt, Matthias Fischer, Louis Chesler, and Martin Eilers.